The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Safety and Efficacy of DAAs (Daclatasvir+Asunaprevir) in patients with chronic hepatitis C
and chronic renal failure will be assessed.
Phase:
Phase 4
Details
Lead Sponsor:
Myeong Jun Song
Collaborators:
Bristol-Myers Squibb Cheongju St. Mary's Hospital, Cheongju, Korea Chungnam National University Hospital Dankook University Eulji General Hospital Eulji University Hospital Konkuk University Hospital Konyang University Hospital Korea University Guro Hospital Saint Vincent's Hospital, Korea Severance Hospital Soonchunhyang University Hospital